Is heparin (anticoagulant) always given before direct current (DC) cardioversion for a patient with paroxysmal supraventricular tachycardia (PSVT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 29, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Heparin Before DC Cardioversion for PSVT

No, heparin is NOT routinely given before DC cardioversion for PSVT—anticoagulation is specifically indicated for atrial fibrillation and atrial flutter, not for typical paroxysmal supraventricular tachycardia (PSVT). 1, 2

Key Distinction: PSVT vs. Atrial Fibrillation

The critical issue here is understanding that PSVT and atrial fibrillation are fundamentally different arrhythmias with different thromboembolic risks:

  • PSVT (including AVNRT and AVRT) does not cause atrial stasis or thrombus formation because atrial mechanical function remains coordinated 1, 2, 3
  • Atrial fibrillation/flutter causes loss of coordinated atrial contraction, leading to blood stasis and thrombus formation, particularly in the left atrial appendage 4

When Heparin IS Required: Atrial Fibrillation/Flutter

For atrial fibrillation or atrial flutter requiring immediate cardioversion due to hemodynamic instability:

  • Administer heparin concurrently with an initial IV bolus followed by continuous infusion 4, 5
  • Target aPTT of 1.5-2.0 times control value 4, 6
  • Continue oral anticoagulation (INR 2.0-3.0) for at least 4 weeks post-cardioversion 4

For AF/flutter of ≥48 hours duration or unknown duration:

  • Either anticoagulate for 3 weeks before and 4 weeks after cardioversion 4
  • OR perform TEE to exclude thrombus, then give heparin before cardioversion and oral anticoagulation for 4 weeks after 4, 5

For AF/flutter <48 hours duration:

  • Anticoagulation may be based on thromboembolic risk assessment (CHA₂DS₂-VASc score) 4, 5
  • If cardioversion is performed, still provide post-cardioversion anticoagulation for at least 4 weeks 7

Management of PSVT Requiring Cardioversion

For hemodynamically unstable PSVT:

  • Perform immediate synchronized cardioversion without anticoagulation 1, 2, 3
  • No heparin is needed before or after cardioversion 1, 3

For hemodynamically stable PSVT:

  • First-line: vagal maneuvers (modified Valsalva maneuver, 43% effective) 1, 3
  • Second-line: IV adenosine (91% effective) 1, 3
  • Alternative medications: calcium channel blockers or beta-blockers 2, 3
  • Cardioversion is reserved for refractory cases or hemodynamic instability 2, 3

Critical Pitfall to Avoid

Do not confuse PSVT with atrial fibrillation. The electrocardiographic features are distinct:

  • PSVT: Regular narrow-complex tachycardia (150-250 bpm), P waves hidden or inverted, abrupt onset/termination 2, 8
  • Atrial fibrillation: Irregularly irregular rhythm, absent P waves, fibrillatory waves 4

If there is any diagnostic uncertainty on a single-lead rhythm strip, obtain a 12-lead ECG immediately to confirm the diagnosis before treatment 8. Misdiagnosing atrial fibrillation as PSVT could lead to cardioversion without appropriate anticoagulation and subsequent stroke risk 4.

References

Research

Paroxysmal Supraventricular Tachycardia: Pathophysiology, Diagnosis, and Management.

Critical care nursing clinics of North America, 2016

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Contraindications and Precautions for Cardioversion in Atrial Fibrillation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Heparin Dosing for Atrial Fibrillation Following Upper Extremity AV Fistula Creation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Anticoagulation Guidelines for ICU-Acquired Paroxysmal Atrial Fibrillation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Paroxysmal supraventricular tachycardias.

The Journal of emergency medicine, 1996

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.